IART Relative Valuation
IART's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IART is overvalued; if below, it's undervalued.
Historical Valuation
Integra Lifesciences Holdings Corp (IART) is now in the Undervalued zone, suggesting that its current forward PE ratio of 5.22 is considered Undervalued compared with the five-year average of 15.28. The fair price of Integra Lifesciences Holdings Corp (IART) is between 25.67 to 46.37 according to relative valuation methord. Compared to the current price of 12.73 USD , Integra Lifesciences Holdings Corp is Undervalued By 50.42%.
Relative Value
Fair Zone
25.67-46.37
Current Price：12.73
50.42%
Undervalued
5.22
PE
1Y
3Y
5Y
Trailing
Forward
8.07
EV/EBITDA
Integra Lifesciences Holdings Corp. (IART) has a current EV/EBITDA of 8.07. The 5-year average EV/EBITDA is 13.58. The thresholds are as follows: Strongly Undervalued below 7.49, Undervalued between 7.49 and 10.54, Fairly Valued between 16.63 and 10.54, Overvalued between 16.63 and 19.68, and Strongly Overvalued above 19.68. The current Forward EV/EBITDA of 8.07 falls within the Undervalued range.
9.55
EV/EBIT
Integra Lifesciences Holdings Corp. (IART) has a current EV/EBIT of 9.55. The 5-year average EV/EBIT is 15.36. The thresholds are as follows: Strongly Undervalued below 8.69, Undervalued between 8.69 and 12.03, Fairly Valued between 18.70 and 12.03, Overvalued between 18.70 and 22.04, and Strongly Overvalued above 22.04. The current Forward EV/EBIT of 9.55 falls within the Undervalued range.
0.56
PS
Integra Lifesciences Holdings Corp. (IART) has a current PS of 0.56. The 5-year average PS is 2.43. The thresholds are as follows: Strongly Undervalued below 0.35, Undervalued between 0.35 and 1.39, Fairly Valued between 3.48 and 1.39, Overvalued between 3.48 and 4.52, and Strongly Overvalued above 4.52. The current Forward PS of 0.56 falls within the Undervalued range.
5.92
P/OCF
Integra Lifesciences Holdings Corp. (IART) has a current P/OCF of 5.92. The 5-year average P/OCF is 17.21. The thresholds are as follows: Strongly Undervalued below 4.79, Undervalued between 4.79 and 11.00, Fairly Valued between 23.42 and 11.00, Overvalued between 23.42 and 29.63, and Strongly Overvalued above 29.63. The current Forward P/OCF of 5.92 falls within the Undervalued range.
14.04
P/FCF
Integra Lifesciences Holdings Corp. (IART) has a current P/FCF of 14.04. The 5-year average P/FCF is 21.49. The thresholds are as follows: Strongly Undervalued below 1.86, Undervalued between 1.86 and 11.67, Fairly Valued between 31.31 and 11.67, Overvalued between 31.31 and 41.12, and Strongly Overvalued above 41.12. The current Forward P/FCF of 14.04 falls within the Historic Trend Line -Fairly Valued range.
Integra Lifesciences Holdings Corp (IART) has a current Price-to-Book (P/B) ratio of 0.94. Compared to its 3-year average P/B ratio of 1.74 , the current P/B ratio is approximately -45.76% higher. Relative to its 5-year average P/B ratio of 2.42, the current P/B ratio is about -61.06% higher. Integra Lifesciences Holdings Corp (IART) has a Forward Free Cash Flow (FCF) yield of approximately -3.90%. Compared to its 3-year average FCF yield of 3.11%, the current FCF yield is approximately -225.51% lower. Relative to its 5-year average FCF yield of 3.55% , the current FCF yield is about -209.79% lower.
0.94
P/B
Median3y
1.74
Median5y
2.42
-3.90
FCF Yield
Median3y
3.11
Median5y
3.55
Competitors Valuation Multiple
The average P/S ratio for IART's competitors is 74.42, providing a benchmark for relative valuation. Integra Lifesciences Holdings Corp Corp (IART) exhibits a P/S ratio of 0.56, which is -99.25% above the industry average. Given its robust revenue growth of -0.61%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IART decreased by 37.41% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -2.97 to -116.47.
The secondary factor is the Revenue Growth, contributed -0.61%to the performance.
Overall, the performance of IART in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Integra Lifesciences Holdings Corp (IART) currently overvalued or undervalued?
What is Integra Lifesciences Holdings Corp (IART) fair value?
How does IART's valuation metrics compare to the industry average?
What is the current P/B ratio for Integra Lifesciences Holdings Corp (IART) as of Aug 06 2025?
What is the current FCF Yield for Integra Lifesciences Holdings Corp (IART) as of Aug 06 2025?
What is the current Forward P/E ratio for Integra Lifesciences Holdings Corp (IART) as of Aug 06 2025?